To study efficacy and safety of diacerein as an add-on therapy to aceclofenac in patients with osteoarthritis of knee

PGIMS Rohtak0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1.Patients above 40 years of age.
•2.Patients newly diagnosed as having knee osteoarthritis based on clinical diagnosis.
•3.Patients having radiographic evidence of OA with a grade of 2 or 3 on Kellgren and Lawrence grading scale.
•4.Patients willing to give a written informed consent.

•1.Radiographic grade IV knee osteoarthritis as per Kellgren and Lawrence classification.
•2.Patients who have earlier been treated with any disease modifying drug.
•3.Patients who have been taking any intra-articular injections for atleast 3 months before the study.
•4.History of accompanying osteoarthritis of the hip of sufficient severity to interfere with the functional assessment of the knee.
•5.Patients with known hypersensitivity to study drug.
•6.History of painful knee condition other than osteoarthritis, gout or post traumatic arthritis.
•7.Patients having history of persistent diarrhea or clinically diagnosed peptic ulcer disease.
•8.Patients with severe renal insufficency, hepatic disease.
•9.Patients having diabetes mellitus.
•10. Patients who refused to give informed consent.

发起方

PGIMS Rohtak